In an open label phase I/II trial, combination BRAF and MEK inhibition with dabrafenib and trametinib (respectively) improved progression free survival from 5.8 months with dabrafenib monotherapy to 9.4 months with combination therapy in metastatic melanoma patients with BRAF V600 mutation [29]. Here, BRAF is linked to metastatic melanoma.